论文部分内容阅读
“以药养医”已成为我国医疗市场的顽疾。一方面,医疗价格被人为地压低, 近两年虽然有所改善,但主要还是政府指导价;另一方面,由于国家对医疗机构的预算投入逐年下降,迫使医院依赖“以药养医”的生存体制。而且国家允许医院在药品方面获取10%-15%的加成利益, 在各类器械、检查设备方面收取5%的管理费。这种药品加成政策使医院和药厂的利益紧密地联系在一起,无疑为医药合谋创造了条件。所以尽管我们有16次的药价下调(有消息指出,发改委正在酝酿第17次调整药价)和持续几年的药
“Taking medicine as medicine” has become a chronic illness in China’s medical market. On the one hand, medical prices have been artificially depressed. Although the improvement has been made in the past two years, the price is mainly guided by the government. On the other hand, the state’s budgetary investment in medical institutions has been declining year by year, forcing hospitals to rely on " Survival system. And the state allows the hospital to obtain 10% -15% of the benefits of the drug, in various types of equipment, inspection equipment charge 5% of the management fee. This policy of drug addiction closely linked the interests of hospitals and pharmaceutical companies, which undoubtedly created conditions for the collusion of pharmaceuticals. So although we have 16 times the drug prices down (there is news that the NDRC is brewing 17th adjustment of drug prices) and for several years of medicine